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Polymorphic diversity in antibody constant domains has long been defined by allotypic
motifs that cross react with the sera of other individuals. Improvements in sequencing
technologies have led to the discovery of a large number of new allelic sequences that
underlie this diversity. Many of the point mutations lie outside traditional allotypic motifs
suggesting they do not elicit immunogenic responses. As antibodies play an important
role in immune defense and biotechnology, understanding how this newly resolved
diversity influences the function of antibodies is important. This review investigates the
current known diversity of antibody alleles at a protein level for each antibody isotype
as well as the kappa and lambda light chains. We focus on evidence emerging for how
these mutations perturb antibody interactions with antigens and Fc receptors that are
critical for function, as well as the influence this might have on the use of antibodies as
therapeutics and reagents.
Keywords: allotypes, Fc receptor, antibody constant domain, antibody alleles, antibody polymorphism, antibody
effector functions, heavy chain diversity, immunoglobulin diversity
INTRODUCTION
Antibodies play an essential role as frontline molecules of adaptive immunity in the fight against
infection and disease. While pathogenic targets can be directly neutralized via binding of antibody
variable domains, binding of the constant domain to specialized Fc receptors on the surface of
immune cells dictates powerful inflammatory or anti-inflammatory responses (1). Together the
remarkable affinity, exquisite specificity, and immune modulation potency of these interactions
have seen antibodies adopted as indispensable reagents in medicine and as diagnostics.
The profile of Fc receptor engagement is, in part, governed by the heavy chain isotype of
the antibody encountered. Immunoglobulin (Ig) isotypes are divided into classes and subclasses
depending on the heavy chain they possess; IgM (µ), IgD (δ), IgG (γ) which encompasses subclasses
IgG1, IgG2, IgG3, IgG4, IgA (α) which encompasses subclasses IgA1 and IgA2, and IgE (ε) (2).
Each isotype is paired with either a kappa (κ) or lambda (λ) light chain to create a tetrameric
immunoglobulin complex capable of triggering unique effector functions. Adding a further level
of complexity, and in spite of the “constant” naming convention, genes of the immunoglobulin
heavy-chain constant (IGHC) and light-chain constant (IGLC) loci are polymorphic, although to a
far lesser extent than the immunoglobulin heavy-chain variable locus (3). IGHC/IGLC polymorphic
diversity has historically been defined by amino-acid mutations in the polypeptide chain that are
immunogenic. Termed allotypes, these mutations were first identified by ex vivo serological studies
in which antibodies from donor sera were observed to trigger agglutination of erythrocytes treated
with host serum (4, 5). Allotypes have been identified for IgG1, IgG2, IgG3, IgG4, IgA2, and
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IgE as well as the kappa light chain (6–8). Before the
ready availability of genetic sequencing techniques, allotyping
provided an excellent method to track genetic linkage between
human populations and ethnic groups thus allowing deeper
understanding of human migration patterns (9), population
genetics (10), and created tools in forensic medicine (11).
More recently, allotypes have been investigated for their
potential role as immunogenic motifs in therapeutic antibodies.
Surprisingly, it appears that allotypes act only as minor
epitopes in monoclonal antibodies and do not appear to elicit
acute rejection (12), although some studies have reported low
levels of pre-existing circulating antibodies against allotypes of
therapeutic monoclonals (13, 14). A key pitfall of serological
detection of allotypes is the difficulty of evaluating immunogenic
responses to immunoglobulin isotypes expressed at low levels in
serum, such as IgE and IgM, signified by a lack of known allotypes
for these classes (8). Furthermore, serological reagents used for
allotype detection are of limited availability, and sourcing of anti-
sera for rare motifs is difficult, meaning some motifs may be
missed (10, 15).
While allotypes have long been the defining feature of Ig
isotype diversity we argue that the richer diversity found at
the allelic level is likely to have profound consequences for
our use and understanding of antibodies. These mutations have
largely been ignored due to a lack of immunogenic phenotype;
however, they likely play a crucial role in host immunity or in
the mechanism of monoclonal antibody drugs (Figure 1A). This
review summarizes the current known natural diversity of human
immunoglobulin constant regions, the implications for antibody
function beyond what is known for historically defined antibody
allotypes, and gaps in our current knowledge of IGHC/IGLC
allele function.
THE CHALLENGES OF IGHC/IGLC
ALLELIC DISCOVERY
The extent of IGHC/IGLC allelic diversity has been overlooked
for many years due to the technical inaccessibility of the
highly homologous IGH genomic locus. Approaches requiring
the assembly of short DNA sequencing reads and genome-
wide association studies (GWAS) have struggled to resolve
individual genes in this locus (16, 17). These challenges have been
compounded by the common practice of sampling circulating
B cells that have undergone multiple instances of unique
rearrangements, including class switch recombination, resulting
in an IGH locus of inconsistent length and composition (17).
It is particularly notable that GWAS gene probes for detection
of single nucleotide polymorphisms (SNPs) in this region are
largely absent from modern arrays and any identified SNPs
have been difficult to assign to the correct immunoglobulin
domain (18). The result has been a slow and very manual
accumulation of known IGHC/IGLC allelic sequence data over
more than 30 years.
Recently, specifically targeted PCR approaches and the
curation of high-quality sequencing data, such as the 1,000
genomes project, have enhanced our ability to detect variation
in this region at the genomic level (19, 20). In the past 2 years
alone, more than 250 new IGHC/IGLC allelic variants have been
discovered. Because a large proportion of the newly discovered
diversity is protein coding and does not map to known allotypes
(Figures 1B, 2), the consequences for antibody function are
unknown. There is agreement with allotype population data in
that IGHC allelic prevalence is heavily biased toward different
ethnicities as evidenced by the differential distribution of alleles
between five superpopulations; Africans, Americans, East Asians,
Europeans, and South Asians (20). Within each allele, variation
is largely confined to certain nucleotide positions suggesting
the functional consequences of these alleles may be driving
evolutionary selection over time. It is likely some of this variation
was introduced via admixture from archaic hominins (21).
Nonetheless, it remains evident that the true breadth of constant
domain allelic diversity can only be uncovered once many more
populations are investigated.




Diversity in the constant domain is inherently linked to antibody
function both in vivo and ex vivo. At a fundamental level,
changes to the amino acid sequence can greatly influence both
antibody assembly and stability. For example, the IgG4 subclass
is well known to carry out Fab-arm exchange to create naturally
bispecific antibodies which are thought to contribute to anti-
inflammatory properties typical of IgG4 antibodies (22, 23).
While most IgG4 alleles have arginine at position 409, IGHG4∗03
has the non-allotypic polymorphism, K409 (Figure 2). This
mutation inhibits Fab-arm exchange by stabilizing CH3-CH3
interactions of the antibody (22, 24). Occurrence of this natural
variant suggests there are benefits to remaining monospecific,
however, these have yet to be explored in detail.
Other IgG subclasses (IgG1, IgG2, IgG3) also have allelic
variants that influence CH3-CH3 interaction stability, despite
not carrying out Fab-arm exchange. These include variations
at positions 392 and 397 which are situated at the edges of
the CH3 dimerization interface (24). Asparagine at position
392 significantly weakens CH3-CH3 interaction compared to
K392 and the resulting IGHG3∗03 allele dissociates significantly
faster than IgG4 molecules. It is proposed these point mutations
influence antibody aggregation dynamics that may be important
for the stability of mixed antibody populations in therapeutic
formulations (25). Mutations found in the CH3 domains of other
subclasses and isotypes may also impact antibody stability but
have yet to be investigated.
Fc Receptor Binding
A delicate balance of immune modulation is mediated by
antibody interaction with Fc receptors. Disrupting or enhancing
binding affinity for key activatory receptors [FcγRs (FcγRI,
FcγRIIa, FcγRIIIa, TRIM21), FcαRs (FcαRI, Fcα/µR), FcεRs
Frontiers in Immunology | www.frontiersin.org 2 August 2020 | Volume 11 | Article 2016
fimmu-11-02016 August 16, 2020 Time: 14:15 # 3
Warrender and Kelton Beyond Allotypic Antibody Diversity
FIGURE 1 | (A) The influence of antibody constant domain diversity on function. Amino acid differences in antibody alleles perturb interaction with Fc receptors,
antigens, and complement proteins, as well as influencing intrinsic antibody stability. Shown in the center is a crystal structure of full length IgG1 [PDB: 1hzh (80)]
with mapped allotype locations (black), additional IgG1 point mutations coded by alleles (purple), and IgK point mutations coded by alleles (green). The light chain
comprises the VL and Cκ domains whereas the heavy chain is made of the VH, CH1, CH2, and CH3 domains. Orange indicates the domains responsible for antigen
binding. Key Fc receptor binding regions of the structure are shaded in purple. (B) IgG allotype motifs. Allotypes are motifs identified by serological cross reactivity
between donors. These motifs are mapped to the same alignment shown in Figure 2 for all IGHG alleles. Residues known to directly interact with Fc receptors are
highlighted in blue (FcγRI) (81), red (FcγRIIa & FcγRIII) (82, 83), and green (FcRn) (84).
(FcεRI, FcεRII) and FcµRs (FcµR, Fcα/µR)] and inhibitory Fc
receptors [FcγR (FcγRIIb)] can have significant consequence.
These interactions are responsible for driving potent antibody-
dependent cell-mediated actions, including cytotoxicity (ADCC),
phagocytosis, trogocytosis, degranulation responses, antiviral
responses, and cytokine release, all of which have been
extensively reviewed elsewhere (26–28). As a general rule, the
strength/pattern of binding to each receptor is correlated to the
intensity of the immune response, with high affinity interactions
directing stronger responses. Extensive mutational studies from
antibody engineering have provided valuable insight into how Fc
domain point mutations can alter antibody function (29–32). Not
only can single heavy chain point mutations massively alter Fc
receptor selectivity ratios (33), but these mutations do not need
to be proximal to receptor binding sites (34).
Investigations into allotypes have long implicated a potential
for perturbed interactions with Fc receptors. In particular,
FcγRIII mediated NK cell cytotoxicity by clinical antibodies
is diminished or enhanced by certain allotypes (35, 36). Very
recently, a systematic study of Fc receptor binding to 27 unique
IgG alleles found variation in the IgG3 class of antibodies
contributed to altered Fc receptor binding (37). These effects
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FIGURE 2 | Unique amino acid mutations within IgG heavy chain alleles (IGHG) of all subclasses. IGHG (IgG1, IgG2, IgG3, IgG4) were obtained from IMGT and pmIG
databases, aligned, and corresponding allotype or isoallotype motifs mapped as indicated in bold (3, 5, 20). Isoallotypes have only been reported in certain
subclasses despite the often ubiquitous presence of these motifs. Residues are numbered according to the Eu numbering convention. Colored boxes represent
unique amino acid differences between alleles that are not associated with known allotypes and for which the functional impact is largely unknown. Residues known
to directly interact with Fc receptors are highlighted in blue (FcγRI) (81), red (FcγRIIa & FcγRIII) (82, 83), and green (FcRn) (84). H1, H2, H3, H4 indicate amino acid
sequences for each of the hinge exons in IGHG3 alleles. §Partial alleles where complete allele sequence information is missing.
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were linked independently to both variation in the hinge length
and to the presence of unique point mutations at positions 291,
292, and 296 in the CH2 domain. Differences in observed Fc
receptor binding led to altered ADCC capacity thus highlighting
the functional consequence of this diversity. Natural heavy
chain variation is also proving to be beneficial for passive
immunization strategies. A potent anti-HIV antibody response
was linked to the expression of two IGHG3 alleles; IGHG3∗01m
(GenBank:MK679684) and IGHG3∗17 (38). Both alleles carry
polymorphisms (E419 and K392, respectively) that do not define
allotypes but are implicated in improved binding to FcγRIII and
FcγRIIb receptors and enhanced ADCC responses.
FcRn Binding
Neonatal receptor binding (FcRn) is important for enhancing
the circulating half-life of antibodies in serum, the transfer of
passive immunity to neonates, and in the uptake of exogenous
antibody bound antigens (39–41). Antibodies are recycled in
a pH dependent manner with binding occurring at ∼pH 6.5
within pinocytosed endosomes and released when returned to
pH 7.4 at the cell surface. Altering the binding affinity of the
CH2/CH3 domain interface at either of these pHs can have
immense consequence and has been well established for allotypic
variants of clinical antibodies (42). In certain IgG3 alleles, a
single amino acid change, R435, reduces binding to FcRn at
low pH despite enhancing binding at neutral pH (43, 44). This
results in out-competition by circulating IgG1 antibodies for
FcRn binding sites and a greatly shortened half-life relative to
other IgG subclasses.
Classical C1q-Mediated Complement
Binding of C1q to IgG or IgM is the first step in the
classical complement-dependent cytotoxicity (CDC) cascade
that culminates with the formation of a membrane attack
complex that lyse target cells (45). As with FcγR binding,
C1q interacts with amino acids in the CH2 domain so
variants at or near this interface can influence binding
and thus CDC immune response. Although allotypic effects
have been reported to affect C1q binding in other species
(46), little effect has been reported in humans (47). Instead,
alterations to the length of the hinge region in IgG3,
particularly truncations, have been shown to enhance C1q
activity (48). A wide range of allelic hinge diversity is found
in IgG3, but it is currently unknown how this might influence
C1q binding.
Antigen Binding
Selective antigen recognition underpins both the evolutionary
and clinical success of antibodies. A longstanding dogma of
immunology postulates antigen binding is determined by the
variable domains of the heavy and light chains while effector
function and isotype are determined by the constant domains
alone (49). However, there is growing evidence that this theory
is oversimplified. Not only do B cell superantigens bind non-
canonically to antibody domains (50), but some antigen binding
domains influence effector function and constant domain
selection can affect antigen binding (18, 49, 51). Abundant
evidence from isotype switched antibodies possessing identical
variable domains indicates point modifications to the CH1
domain can affect the conformation of the antigen binding pocket
and subsequent affinity (52, 53). Several alleles (IGHG2∗02,
∗04, ∗09 and IGHG3∗17, ∗18) have amino acid substitutions
in the CH1 domain, and diversity in light chain constant
domains is well established, although to our knowledge the
influence of these mutations on antigen binding have not
been investigated. It is less intuitive to note mutation in
the CH2/CH3 domains can also propagate allosteric changes
to modulate antigen binding (54). Differences in antigen
binding have been found for different alleles with the same
variable region, although without high resolution analysis to
determine exactly which mutations are contributing to the
effect (55).
IMPLICATIONS OF CONSTANT DOMAIN
DIVERSITY IN DISEASE
Immunoglobulin allotypes and haplotypes have long been
associated with susceptibility to infections and diseases including
breast cancer (56), autoimmunity (57, 58), malaria (39,
59), herpes (16, 60, 61), and hepatitis C (62, 63). More
recently, studies have even linked constant domain diversity
to longevity observed in certain populations (64). Often
allotypic diversity is linked with serum abundance of antibodies
targeting the infectious agent. For instance, antibody titers
against Hepatitis C virus E1E2 glycoproteins are, in part,
determined by G1m1, G1m17, G3m5, and G3m13 motifs
(Figure 1B) (63) and are prognostic for faster recovery (65).
Similarly, breast cancer patients carrying the G2m23 (56)
or Km1 kappa allotypes (66) tend to have higher levels of
IgG antibodies, which can be associated with better patient
outcomes. The focus on allotypic motifs in these studies means
the exact allelic context is uncertain and therefore which
amino acids may be contributing to the observed phenotypes
remains unknown.
In recent years, high quality genomic datasets have provided
evidence implicating non-allotypic IGHC diversity in human
disease. In line with the observations from allotypic analyses,
a key consequence of variation is marked differences in
antibody serum abundance. Jonsson et al., reported variant
P189T (SNP:rs11627594) in the CH1 domain of IGHG2∗02
decreases global expression of IgG molecules (67). Importantly,
their evidence also extended to isotypes other than IgG for
which less diversity has been discovered to date. The study
found a novel variant of IGHA1, also reported by Khatri
et al. (encoding P85.1S; IMGT numbering, SNP:rs117775520),
is associated with high IgA concentration. In Alzheimer’s
disease, advances in the quality of exome sequencing have
led to data reporting an association of three IGHG3 alleles
with severity (68). One of these variants (Y296F) is non-
allotypic and found in alleles IGHG3∗11, IGHG3∗12, IGHG3∗26.
The underlying mechanism for this association is yet to be
explored. Similarly, SNP associations have been reported in
IGHG3∗18 (S176Y SNP:rs201430154) to increase the risk of
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inhibiting components of protein replacement therapies in
hemophilia (69). The importance of considering non-allotypic
allelic variation is further highlighted by the discovery of a
SNP in the cytoplasmic tail of IgG1 which is prevalent in
cases of systemic lupus erythematosus (57). This variant has
major implications for the humoral response upon infection or
vaccination, and in autoimmune disorders, by enhancing IgG1
expression. Beyond these studies, the role of constant domain
diversity in disease remains broadly underexplored, especially in
light of new allele discoveries, and despite a critical antibody role
in adaptive immune defense.
POTENTIAL IMPLICATIONS FOR
THERAPEUTICS AND DIAGNOSTICS
Analysis of anti-drug antibodies has suggested that unique
variable region motifs rather than allotypes have greater
immunogenic potential (12, 70). Nonetheless genetic variation
in antibody constant domains is considered critical to antibody
design and most clinical antibodies are either of the G1m17
or G1m3 allotypes (11). We also note the emergence of
therapeutic antibody formats entirely lacking constant domains
e.g., Nanobodies or BiTEs (71). As IGH allelic discovery
accelerates, the choice of therapeutic backbones will become
even wider and allogenic potential should not be discounted.
Additional consideration needs to be given to the influence
of allelic selection on immune effector function especially
considering the polymorphisms present in several of the Fc
receptor genes (FcγRIIa-R131H, FcγRIII-F156V) (72). More
studies are required to determine the influence of new allelic
diversity on potential effector functions. The influence of
diversity in the constant domain also impacts antibody serum
persistence, especially when in competition with natural allelic
variants that may have vastly different FcRn binding affinities.
Both monoclonal and polyclonal antibodies continue to be
essential reagents for rapid diagnostic testing and as probes in
research despite contributing to a “crisis of reproducibility” in the
scientific literature (73). Constant domain diversity can introduce
error in two primary ways. First, purification of these reagents
from complex mixtures such as serum or culture media requires
the use of chromatographic approaches. The commonly used Fc-
binding protein, Protein A, can only bind to and purify certain
allelic variants of IgG3 carrying H435 (44, 74). Missing certain
antibody subclasses could impact the functional composition
of certain antibody preparations. Second, detection blind spots
are created as common secondary detection-antibodies have
incomplete reactivity to all antibody alleles or may even possess
unwanted cross-reactivity to other isotypes (75). A key example is
the discovery of an FDA approved anti-Kell monoclonal that fails
to detect IgG3∗03 and IgG3∗13 antibodies, a false-negative result
that could lead to hemolytic complications in new-borns.
FUTURE PERSPECTIVES
The discovery of large numbers of new alleles in recent years
exemplifies the idea that much of the diversity within the
constant region of antibodies has been technically inaccessible
and therefore largely underestimated. It is probable the full extent
of diversity is yet to be realized, as suggested by comparative
genomics studies in non-human species (76), especially for
antibody isotypes other than IgG and for kappa/lambda light
chains. High quality genomic assemblies such as the upcoming
“All of Us” million genome project have the potential to
provide rich haplotype information for the IgH region (77).
We highlight the recent development of new genomics tools
and databases specifically aligned with diversity in this region.
Rodriguez et al., report the use of a novel bioinformatics
tool, called IGenotyper, used in conjunction with IGH-targeted
long-read sequencing to characterize variation in the IGH
locus in eight samples (78). This technology can be readily
multiplexed to enable population-scale analyses. Furthermore,
a population matched IG (pmIG) database1 has been released
which compiles known immunoglobulin allelic variants from the
1000 Genomes project.
Several questions are inevitably raised as new diversity is
discovered. Key among these is how constant domain diversity
influences the immune response with implications for identifying
those at risk for disease, infection susceptibility, and in the
design of more effective vaccine strategies. There is growing
evidence that antibodies can interact with non-canonical Fc
receptors (TRIM21, DC-SIGN) and display functions that are
not typical of antibodies. This includes activities characteristic
of proteins (enzymes, cytokines, or chaperones) and the use
of atypical means to neutralize pathogens or regulate the
immune system (79). The role of constant domain diversity
has not yet been investigated for these instances. Likewise,
the influence of IGLC diversity on antibody function will be
important to explore in greater depth. Together we expect
this information will enhance the design and delivery of
next-generation antibody drugs and enable higher accuracy in
diagnostic approaches.
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